COVID-19 in MS: Initial observations from the Pacific Northwest.

Published on Sep 3, 2020in Neuroimmunology and Neuroinflammation7.724
· DOI :10.1212/NXI.0000000000000783
James D. Bowen63
Estimated H-index: 63
(UW: University of Washington),
Justine Brink1
Estimated H-index: 1
(UW: University of Washington)
+ 4 AuthorsPavle Repovic8
Estimated H-index: 8
(UW: University of Washington)
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1
📖 Papers frequently viewed together
178 Citations
104 Citations
139 Citations
#1Gavin Giovannoni (QMUL: Queen Mary University of London)H-Index: 105
#2Christopher Hawkes (QMUL: Queen Mary University of London)H-Index: 91
Last. Julian Gold (QMUL: Queen Mary University of London)H-Index: 26
view all 6 authors...
113 CitationsSource
#1Pavan K. Bhatraju (Fred Hutchinson Cancer Research Center)H-Index: 9
#2Bijan J Ghassemieh (Fred Hutchinson Cancer Research Center)H-Index: 1
Last. Carmen Mikacenic (Fred Hutchinson Cancer Research Center)H-Index: 17
view all 18 authors...
Abstract Background Community transmission of coronavirus 2019 (Covid-19) was detected in the state of Washington in February 2020. Methods We identified patients from nine Seattle-area hospitals w...
1,476 CitationsSource
Abstract Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of...
14.1k CitationsSource
Cited By25
#1Aaron Miller (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 22
Teriflunomide, a once daily, oral disease-modifying therapy, has demonstrated consistent efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis (MS) and with a first clinical episode suggestive of MS treated up to 12 years. This review is an update to a previous version that examined data from the teriflunomide core clinical development program and extension studies. Data have since become available from active comparator trials with other disease-modifying ther...
#1S. L. Apostolos-Pereira (USP: University of São Paulo)H-Index: 7
#2Lis Campos Ferreira (UFS: Universidade Federal de Sergipe)H-Index: 1
view all 0 authors...
Background and Objectives null To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD). null Methods null The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register the...
Abstract null null In this consensus statement, we provide updated recommendations on multiple sclerosis (MS) management during the COVID-19 crisis and the post-pandemic period applicable to neurology services around the world. null Statements/recommendations were generated based on available literature and the experience of 13 MS expert panelists using a modified Delphi approach online. null The statements/recommendations give advice regarding implementation of telemedicine; use of disease-modi...
2 CitationsSource
#1Verónica CabreiraH-Index: 3
#2Pedro AbreuH-Index: 9
Last. Maria José SáH-Index: 21
view all 5 authors...
Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modifying therapies (DMTs) and their immune reactions is vital to analyze vaccine response dynamics. A systematic review on COVID-19 course and outcomes in patients receiving different DMTs was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Emerging data on SARS-CoV-2 vaccines was used to elaborate recommendations. Data from 4417 patients sugges...
#1Júlia Leão Batista Simões (Universidade Federal da Fronteira Sul)H-Index: 2
#2Julia Beatrice de Araújo (Universidade Federal da Fronteira Sul)H-Index: 1
Last. Margarete Dulce Bagatini (Universidade Federal da Fronteira Sul)H-Index: 22
view all 3 authors...
The virus "acute respiratory syndrome coronavirus 2" (SARS-CoV-2) is the etiologic agent of coronavirus disease 2019 (COVID-19), initially responsible for an outbreak of pneumonia in Wuhan, China, which, due to the high level of contagion and dissemination, has become a pandemic. The clinical picture varies from mild to critical cases; however, all of these signs already show neurological problems, from sensory loss to neurological diseases. Thus, patients with multiple sclerosis (MS) infected w...
1 CitationsSource
#1Andrea M Kuczynski (U of T: University of Toronto)
#2Jiwon Oh (U of T: University of Toronto)H-Index: 27
Multiple sclerosis (MS) is an inflammatory disease that causes chronic neurological disability in young adults. Modulation of sphingosine 1-phosphate (S1P) receptors, a group of receptors that, among other things, regulate egression of lymphocytes from lymph nodes, has proven to be effective in treating relapsing MS. Fingolimod, the first oral S1P receptor modulator, has demonstrated potent efficacy and tolerability, but can cause undesirable side effects due to its interaction with a wide range...
OBJECTIVE We systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS). METHODS We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19. RESULTS From an initial 2,679 publications and 3,138 conference abstract...
9 CitationsSource
#1Marzia Fronza (University of Cagliari)H-Index: 2
#2Lorena LoreficeH-Index: 18
Last. Eleonora Cocco (University of Cagliari)H-Index: 32
view all 4 authors...
Multiple sclerosis (MS) is a complex disease of the central nervous system that can cause permanent disability in young adults. A large armamentarium is available for its management and is increasing over time. Ozanimod is an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulator family recently approved in different countries for MS with active disease. It selectively modulates S1PR1 and S1PR5 to prevent autoreactive lymphocytes from entering the central nervous system (CN...
#1Steven Willows (U of A: University of Alberta)H-Index: 6
#2S.B. Alam (U of A: University of Alberta)H-Index: 1
Last. Marianna Kulka (U of A: University of Alberta)H-Index: 7
view all 4 authors...
The coronavirus disease 2019 (COVID-19), a serious respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global pandemic. Canada reported its first case of COVID-19 on 25th January 2020. By March 2020 the virus had spread within Canadian communities reaching the most frail and vulnerable elderly population in long-term care facilities. The majority of cases were reported in the provinces of Quebec, Ontario, Alberta and British Columbia a...
1 CitationsSource
#1Pobitra BorahH-Index: 4
#2Pran Kishore DebH-Index: 13
Last. Vinayak SinghH-Index: 14
view all 11 authors...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to the angiotensin-converting enzyme 2 (ACE2) receptor and invade the human cells to cause COVID-19-related pneumonia. Despite an emphasis on respiratory complications, the evidence of neurological manifestations of SARS-CoV-2 infection is rapidly growing, which is substantially contributing to morbidity and mortality. The neurological disorders associated with COVID-19 may have several pathophysiological underpinnings, which are...
4 CitationsSource